Remove 2024 Remove Dosage Remove Pharmaceutical Manufacturing
article thumbnail

Development of novel water-soluble inks for 3D-printed polypills

European Pharmaceutical Review

Benefits in manufacturing The authors illustrated MM-IJ3DP using a novel formulation of a soluble polymer, to enable for the first time, Noyes–Whitney release rates to be programmed and modulated through digital design and manufacture. This paper features in the June 2024 issue of the journal Materials Today Advanced.

Dosage 98
article thumbnail

FOPE and PharmaState Academy address HVAC Systems in pharma manufacturing

Express Pharma

On October 6, 2024, the Federation of Pharma Entrepreneurs (FOPE) and PharmaState Academy conducted Session 6 of the PULSE (Pharma Upgradation & Learning Series for Excellence) initiative, focusing on HVAC Systems and Qualification in pharmaceutical manufacturing.

Dosage 97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FOPE and PharmaState Academy’s PULSE initiative delivers insights on water systems and qualification in pharma manufacturing

Express Pharma

On September 22, 2024, the Federation of Pharma Entrepreneurs (FOPE) and PharmaState Academy hosted Session 5 of the PULSE (Pharma Upgradation and Learning Series for Excellence) initiative, focusing on Water Systems and Qualification. Express Pharma serves as the Media Partner, with Trillyum Consulting as the Knowledge Partner.

Dosage 81
article thumbnail

The Fourth Circuit Upholds CMS’ Definition of “Line-Extension Drug” and “New Formulation”

FDA Law Blog: Biosimilars

Gaulkin — On April 10, the Fourth Circuit unanimously affirmed a summary judgment ruling for the Centers for Medicare & Medicaid Services (CMS) regarding the agency’s definitions of “line-extension drug” and “new formulation” for purposes of determining rebates that drug manufacturers may owe the Medicaid Drug Rebate Program (MDRP).

Dosage 57
article thumbnail

CDMO acquires Meppel facility from Astellas

European Pharmaceutical Review

Delpharm has acquired the Meppel pharmaceutical manufacturing facility in the Netherlands from Astellas. The 31,600 square meter facility produces some 40 million finished solid dosage forms each year, including tablets, capsules and pellets. billion in 2024.